Tag Archives: ALDR

Hot Blue Chip Stocks To Own For 2019

Much has been made of the stock market’s record-setting performance since President Donald Trump won the race for the White House back in November.

Read: Yellen may have the clearest explanation for the stock market’s record run

But Dow Jones’s data team offers more insight into how Trump stacks up compared with other presidents in their first 30 days in office, a milepost Trump hits on Feb. 19. The Dow Jones Industrial Average
DJIA, +0.02%
has returned 4.02% as of Friday’s close, which would make the Dow’s performance in the Trump era’s first month the sixth best in percentage terms behind Franklin D. Roosevelt in 1945, after his fourth victorious campaign for the presidency, when blue chips climbed by 4.1%.

Hot Blue Chip Stocks To Own For 2019: Fortress Transportation and Infrastructure Investors LLC(FTAI)

Advisors’ Opinion:

  • [By Logan Wallace]

    These are some of the media stories that may have effected Accern Sentiment’s scoring:

    Fortress Transportation and Infrastructure Investors (FTAI) Lifted to B- at TheStreet (americanbankingnews.com) BidaskClub Upgrades Fortress Transportation and Infrastructure Investors (FTAI) to “Buy” (americanbankingnews.com) Active Mover – Fortress Transportation and Infrastructure Investors LLC (NYSE: FTAI) (alphabetastock.com) Services Stock Buzz: Fortress Transportation and Infrastructure Investors LLC (FTAI) (stocksgeeks.com) Contrasting H&E Equipment Services (HEES) & Fortress Transportation and Infrastructure Investors (FTAI) (americanbankingnews.com)

    Shares of FTAI opened at $16.25 on Friday. The stock has a market cap of $1,365.03, a PE ratio of 135.42 and a beta of 1.56. Fortress Transportation and Infrastructure Investors has a 12-month low of $14.25 and a 12-month high of $20.13.

  • [By Shane Hupp]

    Fortress Transprtn and Infr Investrs (NYSE: FTAI) and WillScot (NASDAQ:WSC) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Hot Blue Chip Stocks To Own For 2019: Baidu Inc.(BIDU)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    In this segment from the Motley Fool Money podcast, host Chris Hill is joined by Jason Moser of Million Dollar Portfolio, David Kretzmann of Hidden Gems Canada, and Aaron Bush of Motley Fool Rule Breakers to address a listener’s question: What’s the best Chinese stock for long-term investors? The team likes Baidu (NASDAQ:BIDU), commonly referred to as “the Google of China,” as well as Tencent (NASDAQOTH:TCEHY), the company behind the extremely popular messaging and social media app WeChat.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    ReTo Eco-Solutions, Inc. (NASDAQ: RETO) fell 9.3 percent to $4.50 in pre-market trading.
    ProPhase Labs, Inc. (NASDAQ: PRPH) shares fell 8.5 percent to $4.50 in pre-market trading after dropping 3.53 percent on Thursday.
    Nordstrom, Inc. (NYSE: JWN) fell 7.5 percent to $47.10 in pre-market trading. Nordstrom reported upbeat results for its first quarter. Comparable-store sales rose 0.6 percent.
    Baidu, Inc. (NASDAQ: BIDU) shares fell 6 percent to $263.00 in pre-market trading. Baidu disclosed that its COO Qi Lu will step down in July 2018.
    Riot Blockchain, Inc. (NASDAQ: RIOT) shares fell 5.6 percent to $8.98 in pre-market trading after climbing 11.88 percent on Thursday.
    Applied Materials, Inc. (NASDAQ: AMAT) fell 5 percent to $51.30 in pre-market trading. Applied Materials reported stronger-than-expected results for its second quarter, but issued weak sales outlook for the third quarter.
    Blink Charging Co. (NASDAQ: BLNK) fell 5 percent to $7.61 in pre-market trading after rising 11.40 percent on Thursday.
    Illumina, Inc. (NASDAQ: ILMN) shares fell 4.7 percent to $255.77 in pre-market trading.
    Vascular Biogenics Ltd (NASDAQ: VBLT) fell 4.6 percent to $2.10 in pre-market trading after reporting a first-quarter earnings miss.
    Campbell Soup Company (NYSE: CPB) fell 3.3 percent to $37.60 in pre-market trading. Campbell Soup reported upbeat Q3 earnings, but sales missed estimates. The company also lowered its FY18 outlook.
    ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares fell 2.7 percent to $17.65 in pre-market trading after reporting a 7.2 million common stock offering

  • [By Dan Caplinger]

    The stock market didn’t see much volatility on Friday, with most major benchmarks finishing the session very close to where they had started. Without much in the way of market-moving news on the national or global front, most investors instead paid attention to the cross-currents involved with monthly options expirations. Some other parts of the financial markets were more interesting, with bond yields easing a bit lower after their big upward push earlier in the week and oil prices taking a break from their recent surge. Yet some individual companies suffered from bad news that sent their shares lower. Baidu (NASDAQ:BIDU), GameStop (NYSE:GME), and Opko Health (NASDAQ:OPK) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Motley Fool Staff]

    In this segment of the Motley Fool Money podcast, host Chris Hill and senior Fool analysts Jason Moser, David Kretzmann, and Jeff Fischer put Baidu (NASDAQ:BIDU) under the microscope. The Chinese search leader has a massive presence in the world’s most populous market, and with revenue up 31%, it’s apparent that it is putting its troubles with the government in Beijing in the rearview mirror. But the stock is still only trading for six times revenue. Time to give it a look?

Hot Blue Chip Stocks To Own For 2019: Astro-Med, Inc.(ALOT)

Advisors’ Opinion:

  • [By Logan Wallace]

    AstroNova (NASDAQ:ALOT) will be issuing its quarterly earnings data before the market opens on Wednesday, August 22nd. Analysts expect the company to announce earnings of $0.12 per share for the quarter.

Hot Blue Chip Stocks To Own For 2019: Stamps.com Inc.(STMP)

Advisors’ Opinion:

  • [By Steve Symington]

    Stamps.com Inc. (NASDAQ:STMP) announced better-than-expected second-quarter 2018 results on Wednesday after the market closed, helped by growth from both its postage and mailing and shipping businesses. The company also closed on one significant acquisition and announced an agreement to purchase an even larger complementary business.

  • [By Ethan Ryder]

    ILLEGAL ACTIVITY WARNING: “Stamps.com (STMP) Given Consensus Recommendation of “Buy” by Analysts” was published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at www.tickerreport.com/banking-finance/3360313/stamps-com-stmp-given-consensus-recommendation-of-buy-by-analysts.html.

  • [By Stephan Byrd]

    Northern Trust Corp increased its stake in shares of Stamps.com Inc. (NASDAQ:STMP) by 5.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 249,278 shares of the software maker’s stock after purchasing an additional 13,495 shares during the period. Northern Trust Corp owned approximately 1.37% of Stamps.com worth $63,079,000 at the end of the most recent reporting period.

Hot Blue Chip Stocks To Own For 2019: Alder BioPharmaceuticals, Inc.(ALDR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    BidaskClub cut shares of Alder Biopharmaceuticals (NASDAQ:ALDR) from a strong-buy rating to a buy rating in a report released on Tuesday.

    A number of other equities research analysts have also weighed in on the company. Goldman Sachs Group initiated coverage on Alder Biopharmaceuticals in a research report on Tuesday, April 24th. They set a neutral rating and a $17.00 price objective on the stock. Mizuho restated a buy rating and set a $29.00 price objective on shares of Alder Biopharmaceuticals in a research report on Wednesday, March 28th. Cowen set a $23.00 price target on Alder Biopharmaceuticals and gave the company a buy rating in a research report on Monday, February 26th. Leerink Swann reiterated an outperform rating on shares of Alder Biopharmaceuticals in a research report on Sunday, March 4th. Finally, Zacks Investment Research lowered Alder Biopharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, May 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. Alder Biopharmaceuticals currently has an average rating of Buy and a consensus target price of $26.33.

  • [By Brian Feroldi]

    Shares of Alder Biopharmaceuticals (NASDAQ:ALDR), a clinical-stage biotech focused on migraines, rose as much as 14% in afternoon trading on Friday. The jump was in response to the news that Teva Pharmaceutical Industries (NYSE:TEVA) is scrapping part of a late-stage study of a potential rival to Alder’s lead compound eptinezumab. Alder’s stock has since cooled off, but was still up about 6% as of 3:58 p.m. EDT.

  • [By Cory Renauer]

    Migraines affect perhaps a billion people the world over, and it’s been three decades since they had a new preventative treatment option. That means there could be enough demand to drive blockbuster sales for a new class of treatments making their way to consumers right now, one of which could come from little Alder Biopharmaceuticals Inc. (NASDAQ:ALDR).

  • [By Joseph Griffin]

    Mizuho reaffirmed their buy rating on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report released on Thursday morning. The brokerage currently has a $29.00 target price on the biopharmaceutical company’s stock.

  • [By Joseph Griffin]

    Alder Biopharmaceuticals Inc (NASDAQ:ALDR) Director Jeffrey T. L. Smith sold 5,040 shares of Alder Biopharmaceuticals stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $18.00, for a total value of $90,720.00. Following the transaction, the director now directly owns 5,871 shares of the company’s stock, valued at approximately $105,678. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

  • [By Ethan Ryder]

    Alder Biopharmaceuticals (NASDAQ:ALDR) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Monday.

Hot Blue Chip Stocks To Own For 2019: Regency Centers Corporation(REG)

Advisors’ Opinion:

  • [By Logan Wallace]

    State of Tennessee Treasury Department raised its holdings in shares of Regency Centers Corp (NYSE:REG) by 402.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 192,496 shares of the real estate investment trust’s stock after purchasing an additional 154,218 shares during the quarter. State of Tennessee Treasury Department’s holdings in Regency Centers were worth $11,353,000 as of its most recent filing with the Securities & Exchange Commission.

  • [By Logan Wallace]

    Fort Washington Investment Advisors Inc. OH purchased a new position in Regency Centers Co. (NYSE:REG) during the first quarter, HoldingsChannel.com reports. The firm purchased 8,200 shares of the real estate investment trust’s stock, valued at approximately $484,000.

  • [By Stephan Byrd]

    These are some of the media headlines that may have effected Accern’s analysis:

    Get Regency Centers alerts:

    Financial Comparison: Regency Centers (REG) vs. CubeSmart (CUBE) (americanbankingnews.com) AlphaGraphics Falls Church Wins Best Operations Award from Franchisor for Continued Managerial Excellence (prnewswire.com) Comparing New Residential Investment (NRZ) & Regency Centers (REG) (americanbankingnews.com) Chimney Rock Shopping Center adds two tenants (njbiz.com) Regency Centers Corp (REG) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)

    A number of research firms recently weighed in on REG. Citigroup upped their target price on shares of Regency Centers from $66.00 to $67.00 and gave the stock a “neutral” rating in a report on Friday, August 17th. Jefferies Financial Group restated a “hold” rating and issued a $67.00 target price on shares of Regency Centers in a report on Wednesday, August 15th. BMO Capital Markets restated a “hold” rating and issued a $62.00 target price on shares of Regency Centers in a report on Thursday, August 2nd. Wells Fargo & Co upped their target price on shares of Regency Centers from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Friday, August 10th. Finally, TheStreet upgraded shares of Regency Centers from a “c+” rating to a “b-” rating in a report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $68.04.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Regency Centers (REG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Safest Stocks To Invest In 2019

Despite several years of steady declines, deadly vehicle crashes are on the rise, according to the most recent data from the National Highway Traffic Safety Administration.

The safest day to be on the road: Tuesday. The most dangerous? Saturday.

That’s according to a newstudy by Avvo, an online legal referral and review site, which analyzed data from NHTSA’s Fatality Analysis Reporting System in 2016 on how many car crash-related fatalities happened across the country by weekday and time of day.

The analysis found that 6,802 lives were lost on Saturday out of the 37,461 road deaths that occurred in 2016. That was 53% higher than the 4,444 deaths that happened on a Tuesday, the day with the least number of crash-related fatalities.

The second and third deadliest days were also associated with the weekend: Friday (5,826) and Sunday (5,809).

Best Safest Stocks To Invest In 2019: ImmuCell Corporation(ICCC)

Advisors’ Opinion:

  • [By Stephan Byrd]

    ImmuCell (NASDAQ:ICCC) released its quarterly earnings results on Monday. The biotechnology company reported ($0.04) earnings per share for the quarter, Bloomberg Earnings reports. ImmuCell had a negative net margin of 1.61% and a negative return on equity of 0.79%.

Best Safest Stocks To Invest In 2019: Smith & Nephew SNATS, Inc.(SNN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Zimmer Biomet (NYSE: ZBH) and Smith & Nephew (NYSE:SNN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

  • [By Stephan Byrd]

    Wells Fargo & Company MN lifted its holdings in Smith & Nephew plc (NYSE:SNN) by 1.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 390,356 shares of the medical equipment provider’s stock after purchasing an additional 5,951 shares during the quarter. Wells Fargo & Company MN owned 0.09% of Smith & Nephew worth $14,893,000 as of its most recent SEC filing.

  • [By Lisa Levin]

     

    Losers
    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

  • [By Benzinga News Desk]

    Weight Watchers (NYSE: WTW) is tipping the scales on Wall Street: Link

    ECONOMIC DATA
    USA Nonfarm Payrolls for Apr 164.0K vs 189.0K Est; Prior 103.0K. Private Payrolls for Apr 168.0K vs 194.0K Est; Prior 102.0K
    Unemployment Rate for Apr 3.90% vs 4.00% Est; Prior 4.10%
    New York Fed President William Dudley is set to speak at 12:45 p.m. ET.
    The Baker Hughes North American rig count report for the latest week is schedule for release at 1:00 p.m. ET.
    Federal Reserve Bank of San Francisco President John Williams will speak at 3:00 p.m. ET.
    Randal Quarles, Vice Chairman for Supervision, is set to speak at 5:30 p.m. ET.
    Dallas Fed President Robert Kaplan will speak at 8:00 p.m. ET.
    Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 8:00 p.m. ET.
    Kansas City Fed President Esther George will speak at 8:00 p.m. ET.
    ANALYST RATINGS
    RBC upgraded Benefitfocus (NASDAQ: BNFT) from Sector Perform to Outperform
    Stephens upgraded FMC (NYSE: FMC) from Equal-Weight to Overweight
    RBC downgraded Colfax (NYSE: CFX) from Outperform to Sector Perform
    Deutsche Bank downgraded Smith & Nephew (NYSE: SNN) from Hold to Sell

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

Best Safest Stocks To Invest In 2019: Cowen Group, Inc.(COWN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ValuEngine cut shares of Cowen Inc Class A (NASDAQ:COWN) from a hold rating to a sell rating in a report published on Friday.

    COWN has been the subject of a number of other reports. BidaskClub upgraded shares of Cowen Inc Class A from a sell rating to a hold rating in a research note on Saturday, April 7th. Sandler O’Neill started coverage on shares of Cowen Inc Class A in a research note on Friday, May 18th. They issued a buy rating and a $19.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. Cowen Inc Class A presently has an average rating of Hold and an average price target of $17.67.

  • [By Ethan Ryder]

    Cowen Inc Class A (NASDAQ:COWN) Director Peter A. Cohen sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 13th. The shares were sold at an average price of $15.19, for a total value of $37,975.00. Following the completion of the sale, the director now owns 698,095 shares in the company, valued at approximately $10,604,063.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

  • [By Joseph Griffin]

    MetLife Investment Advisors LLC bought a new stake in Cowen Group (NASDAQ:COWN) in the fourth quarter, HoldingsChannel.com reports. The fund bought 13,196 shares of the financial services provider’s stock, valued at approximately $180,000.

  • [By Joseph Griffin]

    Waddell & Reed (NYSE: WDR) and Cowen Group (NASDAQ:COWN) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

  • [By Sean Williams]

    According to a new note published this past week by investment firm Cowen (NASDAQ:COWN), the total cannabis market could generate as much as $75 billion in gross annual sales by 2030, up from a previous forecast of $50 billion by 2026.

  • [By Max Byerly]

    Thompson Siegel & Walmsley LLC reduced its stake in Cowen Group (NASDAQ:COWN) by 6.3% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 750,063 shares of the financial services provider’s stock after selling 50,848 shares during the period. Thompson Siegel & Walmsley LLC owned 2.54% of Cowen Group worth $9,900,000 at the end of the most recent quarter.

Best Safest Stocks To Invest In 2019: Alder BioPharmaceuticals, Inc.(ALDR)

Advisors’ Opinion:

  • [By Brian Feroldi]

    Shares of Alder Biopharmaceuticals (NASDAQ:ALDR), a clinical-stage biotech focused on migraines, rose as much as 14% in afternoon trading on Friday. The jump was in response to the news that Teva Pharmaceutical Industries (NYSE:TEVA) is scrapping part of a late-stage study of a potential rival to Alder’s lead compound eptinezumab. Alder’s stock has since cooled off, but was still up about 6% as of 3:58 p.m. EDT.

  • [By Joseph Griffin]

    Mizuho reaffirmed their buy rating on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report released on Thursday morning. The brokerage currently has a $29.00 target price on the biopharmaceutical company’s stock.

  • [By Cory Renauer]

    Migraines affect perhaps a billion people the world over, and it’s been three decades since they had a new preventative treatment option. That means there could be enough demand to driveblockbuster sales for a new class of treatments making their way to consumers right now, one of which could come fromlittle Alder Biopharmaceuticals Inc. (NASDAQ:ALDR).

  • [By Ethan Ryder]

    Needham & Company LLC assumed coverage on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report issued on Wednesday. The brokerage issued a buy rating and a $28.00 price objective on the biopharmaceutical company’s stock.

  • [By Ethan Ryder]

    Alder Biopharmaceuticals (NASDAQ:ALDR) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Monday.

  • [By Stephan Byrd]

    BidaskClub cut shares of Alder Biopharmaceuticals (NASDAQ:ALDR) from a strong-buy rating to a buy rating in a report released on Tuesday.

    A number of other equities research analysts have also weighed in on the company. Goldman Sachs Group initiated coverage on Alder Biopharmaceuticals in a research report on Tuesday, April 24th. They set a neutral rating and a $17.00 price objective on the stock. Mizuho restated a buy rating and set a $29.00 price objective on shares of Alder Biopharmaceuticals in a research report on Wednesday, March 28th. Cowen set a $23.00 price target on Alder Biopharmaceuticals and gave the company a buy rating in a research report on Monday, February 26th. Leerink Swann reiterated an outperform rating on shares of Alder Biopharmaceuticals in a research report on Sunday, March 4th. Finally, Zacks Investment Research lowered Alder Biopharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, May 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. Alder Biopharmaceuticals currently has an average rating of Buy and a consensus target price of $26.33.

Best Safest Stocks To Invest In 2019: EMCORE Corporation(EMKR)

Advisors’ Opinion:

  • [By Max Byerly]

    News stories about EMCORE (NASDAQ:EMKR) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. EMCORE earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave media stories about the semiconductor company an impact score of 45.6118508960632 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

  • [By Peter Graham]

    Small cap fiber-optic networking product Applied Optoelectronics (NASDAQ: AAOI), a potential peer of EMCORE Corporation (NASDAQ: EMKR), Finisar Corporation (NASDAQ: FNSR) and Oclaro Inc (NASDAQ: OCLR), is themostshorted stock on theNASDAQ with short interest of 62.65% according to Highshortnterest.com.

Top 10 Stocks To Own For 2018

Wall Street analysts tend to be a bullish lot, and few have been as bullish as FundStrat’s Thomas Lee, who’s been accused of being a perma-bull. But just as his colleagues seem to be embracing another year of gains, Lee has decided to dial back the optimism. In his 2017 outlook released today, Lee wrote that he expects that S&P 500 to finish the year at 2,275, down a few points from a recent 2,278.72, and could drop as low as 2,150 during the first half of the year. He lists the downside risks:

Bloomberg News

A sloppy White House organization creates confusion on US policy, particularly as tweets become policy. Washington does not pass infrastructure stimulus. Tax reform multiplier is smaller than market is
expecting. Trump fires JanetFed becomes fall guy for Trump when equity markets get volatile. Fed tightens excessively. USD soars. Europe migrant issues deteriorates and crexit worsens. Former President Obama becomes a vocal critic.

Wow. Who would have thunk it?

Top 10 Stocks To Own For 2018: Reinsurance Group of America, Incorporated(RGA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Morgan Stanley downgraded Chipotle (NYSE: CMG) to Equal-Weight.
    UBS downgraded AMC Networks (NASDAQ: AMCX) to Sell.
    Citi upgraded Sealed Air (NYSE: SEE) to Buy.
    Goldman Sachs upgraded Reinsurance Group (NYSE: RGA) to Buy.

  • [By David Sterman]

    My favorite insurers: AIG (NYSE: AIG) (which I discussed a few months ago), Protective Life (NYSE: PL) and Reinsurance Group of America (NYSE: RGA).

Top 10 Stocks To Own For 2018: Aimia Inc. (GAPFF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Aimia (OTCPK:GAPFF) (TSX: AIM, AIM.PR.A, AIM.PR.B, AIM.PR.C)

    As some background, we are intimately familiar with Aeroplan and Air Canada (OTCQX:ACDVF) not just as investors but as extraordinarily heavy consumers. As both an Air Canada top tier elite and Aeroplan top tier member I generate well in excess of 1.5 million Aeroplan miles annually, half from flying Air Canada and its partners and the other half from spending. As consumers we were concerned with Air Canada’s decision (though we expect more details to come out that will alleviate these concerns) but as investors we understand that the fundamental business model of mileage programs are incredibly attractive and that Aimia presents an incredibly rare and lucrative investment opportunity for the investor discerning enough to dig into the company.

Top 10 Stocks To Own For 2018: Intuit Inc.(INTU)

Advisors’ Opinion:

  • [By Asit Sharma]

    It’s tax season — the four months when tax and small-business software providerIntuit Inc.(NASDAQ:INTU) makes most of its profit for the year. On Thursday, Intuit filed its fiscal second-quarter 2017 earnings report and issued a progress report on its tax business so far this year.Tax volumes are well off last year’s pace: Let’s review the details, as well as management’s interpretation, after a look at the headline numbers.

  • [By Alex Jordon]

    A variety of acquisitions ramps up Oracle’s presence in cloud computing, like deals with RightNow, Taleo, and Eloqua. The annual run-rate of their cloud business is already over $1 billion, larger than Workday (WDAY) and SAP (SAP) combined. New customers include British Telecom (BT), BMC Software (BMC), Siemens (SI), Yahoo (YHOO), and Intuit (INTU).

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, Intuit (NASDAQ:INTU) and Tiffany (NYSE:TIF) saw heavy trading following the companies’ quarterly earnings announcements.

    Image source: Getty Images.

Top 10 Stocks To Own For 2018: Tetra Technologies, Inc.(TTI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Wednesday afternoon, the energy sector proved to be a source of strength for the market. Leading the sector was strength from TETRA Technologies, Inc. (NYSE: TTI) and Abraxas Petroleum Corp. (NASDAQ: AXAS).

  • [By Lisa Levin]

    Energy sector was the top gainer in the US market on Wednesday. Top gainers in the sector included TETRA Technologies, Inc. (NYSE: TTI), CARBO Ceramics Inc. (NYSE: CRR), and Atwood Oceanics, Inc. (NYSE: ATW).

Top 10 Stocks To Own For 2018: MBIA, Inc.(MBI)

Advisors’ Opinion:

  • [By Dan Caplinger]

    But some stocks managed to buck the trend and give investors more upbeat outlooks for their prospects. SandRidge Energy (NYSE: SD), MBIA (NYSE:MBI), and LivePerson (NASDAQ:LPSN) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

Top 10 Stocks To Own For 2018: Flagstar Bancorp, Inc.(FBC)

Advisors’ Opinion:

  • [By Dustin Blitchok]

    When Alessandro DiNello was named CEO of Flagstar Bancorp Inc (NYSE: FBC) in 2013, the bank was on a financial precipice.

    The bank’s business was almost entirely mortgages. As the industry unraveled nationally, Flagstar accepted $267 million in TARP money in 2009 — as well as private equity financing — to maintain solvency.

Top 10 Stocks To Own For 2018: NCI Building Systems, Inc.(NCS)

Advisors’ Opinion:

  • [By Monica Gerson]

    NCI Building Systems Inc (NYSE: NCS) posted upbeat results for its second quarter on Tuesday. NCI Building Systems shares rose 1.24 percent to $16.30 in the after-hours trading session.

  • [By Scott Rubin]

    Equity gainers on the day included Chico's FAS, Inc. (NYSE: CHS), which surged more than 12 percent on the day, and Himax Technologies (NASDAQ: HIMX), which climbed almost 9 percent in the wake of an afternoon rally. Losers included NCI Building Systems Inc. (NYSE: NCS), which fell 15 percent after earnings, and H&R Block inc (NYSE: HRB), which fell almost 11 percent on the day after its Q1 results.

  • [By Lisa Levin]

    On Thursday, the industrial sector proved to be a source of strength for the market. Leading the sector was strength from Envirostar Inc (NYSE: EVI) and NCI Building Systems Inc (NYSE: NCS).

Top 10 Stocks To Own For 2018: Alder BioPharmaceuticals, Inc.(ALDR)

Advisors’ Opinion:

  • [By Paul Ausick]

    Alder Biopharmaceuticals Inc. (NASDAQ: ALDR) posted a new 52-week low of $13.50on Tuesday, down nearly 28% compared with Monday’s closing price of $18.70. The stock’s 52-week high is $36.48. Volume totaled more than 12 million shares, about 12 times the daily average of around 720,000. The company reported that its migraine treatment reported a positive result, but investors were not impressed.

Top 10 Stocks To Own For 2018: Kinross Gold Corporation(KGC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Given revised commodity deck forecasts (particularly for Steel and Gold) and improved Balance Sheet health (Steels, Precious and Industrials Metals) we are upgrading our ratings on several stocks in our coverage. We generally favor companies that have already initiated specific self-help, have low-cost assets and are less exposed to China supply and demand dynamics. In Steels, we have increased our rating from Hold to Buy on Nucor (NUE) and from Sell to Hold on US Steel. We have also upgraded Kinross Gold (KGC) to a Hold on valuation…On higher-than-peer valuations, we reiterate Sell-rated Coeur Mining (CDE), Franco-Nevada (FNV), Goldcorp (GG), Teck Resources (TCK) and highly leveraged AK Steel given preference to issue further equity if possible.

  • [By Wayne Duggan]

    Citi also placed Neutral ratings on Goldcorp Inc. (USA) (NYSE: GG), Kinross Gold Corporation (USA) (NYSE: KGC) and Silver Standard Resources Inc. (USA) (NASDAQ: SSRI).

  • [By Monica Gerson]

    Kinross Gold Corporation (USA) (NYSE: KGC) is projected to post a quarterly loss at $0.01 per share on revenue of $808.09 million.

    Crocs, Inc. (NASDAQ: CROX) is expected to report its quarterly earnings at $0.05 per share on revenue of $265.90 million.

  • [By Lee Jackson]

    Kinross Gold Corp. (NYSE: KGC) may be the stock that give investors the most amount of leverage on a gold rebound. Management reduced the company’s annual capital expenditures forecast to $1.45 billion from $1.6 billion, saving $180 million from its cost restructuring initiatives. Cancellation of its upcoming semiannual dividend payment to its shareholders will save $182 million per year. Kinross expects to produce gold at a cost of $1,000 to $1,200 an ounce this year. The Merrill Lynch target is $7.00, and the consensus target is $6.55. The dividend, which soon will be cancelled, has a yield of 2.9%.

Top 10 Stocks To Own For 2018: (SMPQY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The majority owner is Sun Pharma (OTC:SMPQY) (the largest drug business in India). There have been a number of articles that have outlined Sun Pharma and its quest for Taro, but it makes a lot of sense for Sun to want to own all – and not just the majority – of Taro. One big reason is that owning all of Taro means that any investments that Sun makes with Taros $1.2 billion cash hoard will not be diluted by the presence of minority shareholders. Another reason that Sun likely wants Taro is simply because it is very cheap right now. Sun is run by its founder and majority shareholder, Dilip Shanghvi, who is sort of a pharmaceutical value investor who has opportunistically made acquisitions and investments over time, building his firm starting with a loan of $200 in the early 1980s to the multi-billion business it is today.

  • [By SEEKINGALPHA.COM]

    We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ